ClinicalTrials.gg

Program

Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102

Its studies are led by United Immunity.

Furthest: phase 2, since May 18, 20261 company-led study, 1 open or runningNext primary completion: Mar 31, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
United Immunity11 open or runningphase 2since May 18, 2026May 18, 2026Mar 31, 2030phase 2 · NCT07605962

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2026First study: phase 2 study in Advanced CancerFirst studyNCT07605962 · 140 planned · United States

Ahead

  1. Mar 31, 2030Primary completion: phase 2 study in Advanced CancerNCT07605962

TargetBeta

TLR7 →read by rule
“A nanoparticle formulation composed of a Toll-like receptor 7 and 8 (TLR7/8) agonist ”NCIt, by rule

Other programs on TLR7

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312
TLR7 Agonist JNJ-64794964Sino Biopharmaceuticalphase 26
PRTX007ruleprimmune-therapeutics-incphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07605962Advanced Cancer · United States2RecruitingMar 31, 2030140

How it is read

Names in the registry

  • “UI-102”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.